Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

X-Ray Imaging System Enables Scientists to See in Real Time How Effective Treatments are for Cystic Fibrosis

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
A new imaging approach allows researchers to monitor the effectiveness of a treatment for the life-threatening genetic disorder.

Cystic fibrosis affects many of the body’s systems, but most severely the lungs, and currently it can take several months to measure how effective treatment is for the early-fatal lung disease.

Dr. Kaye Morgan, from Monash University (Melbourne; VIC, Australia), and lead researcher of the study, reported that the new X-ray imaging strategy allows researchers to visualize soft tissue structures, for example, the airways, brain, and lungs, which are effectively hidden in standard X-ray images. “At the moment we typically need to wait for a cystic fibrosis treatment to have an effect on lung health, measured by either a lung CT [computed tomography] scan or breath measurement, to see how effective that treatment is,” Dr. Morgan said. “However the new imaging technique allows us for the first time to noninvasively see how the treatment is working ‘live’ on the airway surface.”

Dr. Morgan noted that this X-ray imaging method would enable clinicians and researchers to measure how effective treatments are, and progress new treatments to the clinic at a much quicker rate, a key goal of the investigators. “Because we will be able to see how effectively treatments are working straight away, we’ll be able to develop new treatments a lot more quickly, and help better treat people with cystic fibrosis,” Dr. Morgan said.

Dr. Morgan noted that the new imaging technology, which was developed using a synchrotron X-ray source, may also create new avenues for assessing how effective treatments were for other lung, heart, and brain diseases.

The study’s findings were published August 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Monash University



Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.